Last 212.75 GBp
Change Today +3.75 / 1.79%
Volume 10.3K
As of 4:01 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

skyepharma plc (SKP) Snapshot

Open
213.75 GBp
Previous Close
209.00 GBp
Day High
213.75 GBp
Day Low
212.75 GBp
52 Week High
04/1/14 - 239.75 GBp
52 Week Low
04/29/13 - 38.17 GBp
Market Cap
122.6M
Average Volume 10 Days
944.6K
EPS TTM
0.02 GBp
Shares Outstanding
46.1M
EX-Date
--
P/E TM
133.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for SKYEPHARMA PLC (SKP)

Related News

No related news articles were found.

skyepharma plc (SKP) Related Businessweek News

No Related Businessweek News Found

skyepharma plc (SKP) Details

Skyepharma PLC, a drug delivery company, develops, manufactures, and sells oral and inhalation pharmaceutical products. Its marketed products include flutiform and ZYFLO CR for treating asthma; Relvar Ellipta/Breo Ellipta for asthma and COPD; Anoro Ellipta for COPD; Paxil CR for depression treatment; Requip Once-a-day and Madopar DR to treat Parkinson’s disease; Triglide for treating lipid disorders; Sular to treat hypertension; Diclofenac-ratiopharm-uno for pain/inflammation; and Lodotra/Rayos to treat rheumatoid arthritis. The company’s marketed products also comprise Coruno to treat angina; Xatral OD/Uroxatral for treating BPH (urinary symptoms); Solaraze for actinic keratosis treatment; and EXPAREL, which is used for pain management. Its development pipeline includes SKP-1041, which has completed Phase II clinical trails for sleep maintenance; and SKP-1052, which has completed Phase I clinical trails for use in reducing the risk of nocturnal hypoglycaemia in insulintreated patients. The company markets its products through specialty pharmaceutical companies worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.

79 Employees
Last Reported Date: 03/28/14
Founded in 1910

skyepharma plc (SKP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 567.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 74.0K GBP
Compensation as of Fiscal Year 2013.

skyepharma plc (SKP) Key Developments

SkyePharma plc Reports Audited Consolidated Financial Results for the Year Ended December 31, 2013; Provides Revenue Guidance for the Year 2014

SkyePharma plc reported audited consolidated financial results for the year ended December 31, 2013. For the year, revenue was £62.6 million against £49.9 million for the last year. The increase from 2012 is mainly due to growth in revenues from the supply of flutiform®. Operating profit was £13.6 million against £17.1 million for the last year. Loss before tax from continuing operations was £1.0 million against £10.4 million for the last year. Profit after tax from continuing operations was £0.8 million against loss after tax from continuing operations of £10.6 million for the last year. Total profit for the year attributable to the parent was £0.8 million against total net loss of £4.4 million for the last year. Diluted EPS was 1.7 pence against diluted LPS of 14.9 pence for the last year. Diluted EPS from continuing operations was 1.7 pence against diluted LPS from continuing operations of 36.0 pence for the last year. Net cash generated by operating activities was £14.2 million against £18.3 million for the last year. Purchases of property, plant and equipment was £2.4 million against £0.9 million for the last year. Purchases of intangible assets was £1.1 million against £0.2 million for the last year. Net debt was £84.2 million against £80.7 million for the last year. Pre-exceptional operating profit was £13.6 million against £12.6 million for the same period a year ago. The company expects further substantial growth in revenues in 2014 compared with 2013 mainly from the products launched in 2012 to date, especially flutiform®, Relvar® Ellipta®/Breo® Ellipta®, Anoro™ Ellipta™, and EXPAREL®.

SkyePharma plc, 2013 Earnings Call, Mar 31, 2014

SkyePharma plc, 2013 Earnings Call, Mar 31, 2014

Skyepharma PLC Announces Executive Appointments

Skyepharma PLC announced that John Biles has been appointed a Non-Executive Director, Chairman of the Audit Committee and a member of the Remuneration and Nomination and Governance Committees. Additionally, Jean-Charles Tschudin, who joined the Board as a Non-Executive Director in July 2007, has been appointed Senior Independent Director. Biles is Chairman of the Audit Committees of Bodycote PLC, HellermannTyton Group PLC and Sutton and East Surrey Water PLC and is also Senior Independent Director of Bodycote and Sutton and East Surrey Water.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKP:LN 212.75 GBp +3.75

SKP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioAlliance Pharma SA €7.02 EUR -0.11
BioDelivery Sciences International Inc $7.40 USD +0.27
Depomed Inc $12.83 USD +0.54
Enzon Pharmaceuticals Inc $0.99 USD +0.0897
Flamel Technologies SA $10.60 USD +0.66
View Industry Companies
 

Industry Analysis

SKP

Industry Average

Valuation SKP Industry Range
Price/Earnings 100.0x
Price/Sales 1.6x
Price/Book NM Not Meaningful
Price/Cash Flow 128.5x
TEV/Sales 3.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYEPHARMA PLC, please visit www.skyepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.